Dallas、TXにおける乳がんの臨床試験
Dallasとその周辺地域（約30マイル以内）の拠点で、乳がんに関する55件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- UT Southwest Simmons Cancer Center, Dallas
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
被験者募集中第1/2相
- University of Texas Southwestern, Dallas
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
被験者募集中第2相
- Texas Oncology DFW, Dallas
- The University of Texas Southwestern Medical Center, Dallas
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
被験者募集中第2相
- Texas Oncology, Dallas
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Dallas
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
被験者募集中第3相
- Texas Oncology - DFW ( Site 8003), Dallas
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
被験者募集中第3相
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
被験者募集中第3相
- Texas Oncology-Dallas Presbyterian Hospital ( Site 8000), Dallas
- Parkland Health and Hospital System ( Site 0069), Dallas
- UT Southwestern Medical Center ( Site 0050), Dallas
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Dallas
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
被験者募集中第2相
- University of Texas Southwestern Medical Center, Dallas
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
被験者募集中第3相
- Clinical Trial Site, Dallas
- Clinical Trial Site, Dallas
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Parkland Health and Hospital System, Dallas
- USO - Texas Oncology, Dallas
- UT Southwestern Medical Center, Dallas
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
被験者募集中
- University of Texas Southwestern Medical Center, Dallas
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- Texas Oncology - DFW (Sammons CC), Dallas
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
被験者募集中第3相
- UT Southwestern Medical Center at Redbird, Dallas
- University Of Texas Southwestern Medical Center, Dallas
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
被験者募集中第1/2相
- Baylor Scott & White Research Institute -Texas Oncology, Dallas
- UT Southwestern Medical Center, Dallas
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Texas Oncology - DFW, Dallas
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
被験者募集中第2相
- Texas Oncology - DFW ( Site 8000), Dallas
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Mary Crowley Cancer Research, Dallas
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
被験者募集中第1相
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- UT Southwestern Medical Center, Dallas
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
被験者募集中第1/2相
- Texas Oncology (Worth) - USOR, Dallas
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
被験者募集中第1/2相
- Texas Oncology - Dallas SCRI, Dallas
Susan G. Komen's ShareForCures
被験者募集中観察研究
- Susan G. Komen, Dallas
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Texas Oncology DFW, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- Mary Crowley Cancer Research, Dallas
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- University of Texas Southwestern Medical Center, Dallas
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- Texas Oncology - Dallas Presbyterian Hospital, Dallas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
- The University of Texas Southwestern Medical Center, Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Mary Crowley Cancer Research, Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- Baylor Scott & White Research Institute, Dallas
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
被験者募集中第2相
- Texas Oncology - DFW, Dallas
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
被験者募集中第2相
- UT Southwestern Medical Center-Dallas, Dallas
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- University of Texas Southwestern, Dallas
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Texas Oncology, P.A., Dallas
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
被験者募集中第1/2相
- Texas Oncology Baylor University Medical Center, Dallas
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
被験者募集中第2相
- Parkland Hospital, Dallas
- University of Texas Southwestern Medical Center, Dallas
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
被験者募集中第1相
- UT Southwestern Medical Center, Dallas
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
被験者募集中第2相
- UT Southwestern Medical Center, Dallas
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
被験者募集中第1/2相
- Next Oncology, Dallas
- UTSW Medical Center, Dallas
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
被験者募集中第2相
- Texas Oncology- DFW, Dallas
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
被験者募集中
- UT Southwestern, Dallas
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
被験者募集中第1/2相
- Research Site, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
被験者募集中早期第1相
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
被験者募集中第2相
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas
Converting HR+ Breast Cancer Into an Individualized Vaccine
被験者募集中第2相
- UT Southwestern Medical Center, Dallas
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
被験者募集中第4相
- UT Southwestern Medical Center, Dallas
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
被験者募集中第2相
- UT Southwestern Medical Center, Dallas
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
被験者募集中早期第1相
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Dallas
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
被験者募集中第3相
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
被験者募集中第1相
- University of Texas Southwestern Medical Center, Dallas
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
被験者募集中観察研究
- Texas Oncology - Presbyterian, Dallas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
他の都市における乳がんの試験
- New York City, NY134件の研究
- Houston, TX126件の研究
- Boston, MA111件の研究
- Nashville, TN80件の研究
- Los Angeles, CA72件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Durham, NC63件の研究
- Queens, NY63件の研究
- Chicago, IL58件の研究
- Philadelphia, PA56件の研究
- Baltimore, MD47件の研究
Dallasにおける他の研究
- 非小細胞肺癌52件の研究
- 転移性癌42件の研究
- 心不全42件の研究
- がん（全種類）37件の研究
- 前立腺がん36件の研究
- 大腸癌33件の研究
- 肥満症30件の研究
- 卵巣がん28件の研究
- 膀胱癌27件の研究
- 肺がん27件の研究
- 子宮内膜がん24件の研究
- 心血管疾患23件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。